Carmantadine (, ; developmental code name SCH-15427) is an
antiparkinsonian agent
In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutri ...
of the
adamantane group that was never marketed.
It is
structurally related to
amantadine and shares some of its
pharmacological actions.
Another related drug is
dopamantine.
Carmantadine was first described by 1972 and is said to have reached early
clinical trials.
References
Abandoned drugs
Adamantanes
Antiparkinsonian agents
Azetidines
Carboxylic acids
Drugs with unknown mechanisms of action
{{Pharma-stub